What Happened
The lead pharmacy technician at ContinuumRx of Central Alabama in Birmingham diluted opioid IV bags meant for terminally ill hospice and homecare patients so he could feed his own opioid addiction.
ContinuumRx compounded IV bags containing morphine and hydromorphone for palliative care of hospice and homecare patients, most of them terminally ill with cancer and suffering breakthrough pain, and distributed those bags to customers including Alacare Home Health & Hospice, New Beacon Hospice, Lakeview Homecare and Hospice, Comfort Care Hospice, and Kindred Hospice. As the lead technician, he prepared the vast majority of the company's IV bags, which helped conceal his scheme.
Between December 2014 and September 2016, when ContinuumRx ended his employment, he surreptitiously removed vials of morphine sulfate and hydromorphone hydrochloride from the company's locked inventory, withdrew the drug with a syringe, and replaced the withdrawn amount with saline or sterile water. He then returned the diluted vials to inventory undetected and later used them to compound IV bags that were distributed and administered to hospice and homecare patients — knowing that terminally ill patients in excruciating pain would receive diluted medication. He pleaded guilty to tampering with a consumer product in reckless disregard for the risk of death or serious injury, and on February 21, 2018, was sentenced to five years in federal prison.
What Went Wrong
A single technician was able to dilute controlled-substance vials undetected for nearly two years because the pharmacy's compounding and inventory controls did not catch tampered stock before it reached patients. Key failures included:
- One technician prepared the vast majority of the pharmacy's IV compounds, concentrating control over the process in a single person with no independent verification.
- Vials removed from locked inventory and later returned were not checked for tampering, weight, or seal integrity before being used in compounding.
- No potency or volume testing on compounded IV bags caught the substitution of saline or sterile water for the prescribed opioid.
- Because the diluted bags were shipped out to external hospice and homecare agencies, there was no closed-loop way for the dispensing pharmacy to learn that patients were receiving under-dosed pain medication until the technician's employment ended.
How It Could Have Been Prevented
- Require a second staff member to independently verify vial weight or volume before use in compounding, rather than relying on one technician for the majority of preparations.
- Inspect returned or previously accessed vials for tamper evidence — reglued caps, puncture marks, or seal irregularities — before they re-enter usable inventory.
- Periodically test compounded IV bags for potency, especially for high-risk drugs like morphine and hydromorphone destined for hospice patients who cannot easily report inadequate pain control.
- Build a feedback channel with receiving hospice and homecare agencies so unexplained reports of poor pain control are escalated back to the compounding pharmacy as a possible tampering signal.
- Rotate or dual-control high-risk compounding duties so no single employee has unsupervised, near-exclusive access to a facility's controlled-substance IV production.
Related Guidance
- Tough Issues — High-risk scenarios with annotated SQL for analyzing compounding and inventory-return gaps.
- 15 Red Flags of Drug Diversion — Behavioral and transactional indicators including tampered vials and concentrated access.
- Hospital Diversion Prevention Checklist — Facility self-assessment, 8 sections 63 items, including compounding and inventory-control sections.
- Controlled Substance Inventory Requirements — Biennial inventory requirements and recordkeeping practices that surface losses.